Overview

Bioavailability of Two Sustained-release Theophylline Products in Healthy Males

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to compare the bioavailability of 350 mg Bronchoretard® - a sustained-release theophylline (anhydrous) product with respect to the reference product, Theo Dur® 300 mg theophylline anhydrous (sustained-release product) by comparing the rate and extent of absorption of theophylline based on both single and multiple-dose profiles.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Theophylline